首页> 外文期刊>International journal of molecular medicine >Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway
【24h】

Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway

机译:氨氯普林酸盐与穴位应用中医护理对PI3K / AKT路径治疗肾功能衰竭及高血压的影响

获取原文
获取原文并翻译 | 示例
           

摘要

To study the effect and molecular mechanisms of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment methods of renal failure and hypertension. A total of 60 cases of renal failure hypertension were randomly divided into the Control group and the Treatment group. The control group was treated with amlodipine besylate, while the treatment group was treated with amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing. A rat model of renal failure hypertension was established. Rats were divided into the sham group, model group, NC group (treated with amlodipine besylate) and treatment group (treated with amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing). Rats were given drugs at 10-20 weeks of age to observe their general condition and detect changes of blood pressure, blood biochemical indices and urine index. The pathological changes of renal tissue were examined by hematoxylin and eosin staining, and the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)9 were detected by immunohistochemistry. Reverse transcription-quantitative polymerase chain reaction was used to determine mRNA expression of phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and endothelin (ET)-1 and western blotting was used to detect the expression of phosphorylated (p)-PI3K/PI3K, p-AKT/AKT and p-nuclear factor (NF)-kappa B p65/NF-kappa B p65 protein. Systolic and diastolic blood pressures in Treated group patients were significantly lower compared with in Control group patients. The systolic and diastolic blood pressure of rats were significantly decreased and blood urea nitrogen (BUN), carbapenem-resistant Enterobacteriaceae (CRE), N-acetyl-beta-D-glucosaminidase (NAG), urine protein (UP) and blood urea protein (BUP), contents were significantly decreased following amlodipine besylate treatment. The expression of VEGF and matrix metallopeptidase 9 protein were significantly decreased, but the expression of PI3K, AKT mRNA and p-PI3K/PI3K, p-AKT/AKT protein were significantly increased. ET-1 mRNA and p-NF-kappa B p65/NF-kappa B protein were significantly increased. The pathological alterations of renal tissue were improved and the pathological changes of glomerulus, tubule and interstitium were alleviated. Amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing can effectively reduce the systolic pressure and diastolic pressure of patients, and improve the symptoms and signs of patients, which may be associated with the regulation of the expression of PI3K/AKT pathway, so as to regulate the expression of BUN, CRE, UP, BUP and NAG.
机译:研究氨氯地平苯磺酸盐的效果和分子机制联合中医护理对肾功能衰竭及高血压治疗方法的影响。总共60例肾功能衰竭高血压随机分为对照组和治疗组。对照组用氨氯地平苯磺酸盐处理,而治疗组用氨氯化氨坡苯磺酸盐配合与中医护理的穴位应用。建立了肾功能衰竭高血压大鼠模型。将大鼠分为假组,模型组,NC组(用氨氯地脂酸盐酸盐处理)和治疗组(用氨氯地平苯磺酸盐处理,结合中医护理的穴位应用)。大鼠在10-20周龄的药物中给药,以观察其一般情况并检测血压,血液生化指数和尿枝的变化。通过苏木精化检查肾组织的病理变化,并通过免疫组化检测血管内皮生长因子(VEGF)和基质金属蛋白酶(MMP)9的表达。逆转录定量聚合酶链反应用于测定磷酸膦酸3-激酶(PI3K),蛋白激酶B(akt)和内皮素(ET)-1和Western印迹的mRNA表达用于检测磷酸化(P)的表达 - PI3K / PI3K,P-AKT / AKT和P核因子(NF)-KAPPA B P65 / NF-KAPPA B P65蛋白。与对照组患者相比,治疗组患者的收缩系和舒张血压显着降低。大鼠的收缩性和舒张压血压显着降低,血尿尿素氮(BUN),耐肠癌肠杆菌(CRE),N-乙酰β-D-葡糖胺酶(NAG),尿蛋白(UP)和血液脲蛋白(在氨氯地平的苯磺酸盐处理后,含量显着降低。 VEGF和基质金属肽酶9蛋白的表达显着降低,但显着增加了PI3K,AKT mRNA和P-PI3K / PI3K,P-AKT / AKT蛋白的表达。 ET-1 mRNA和P-NF-Kappa B P65 / NF-Kappa B蛋白显着增加。改善了肾组织的病理变化,缓解了肾小球,小管和间质的病理变化。氨氯堇属苯磺酸盐与穴位应用中医护理的应用可以有效降低患者的收缩压和舒张压,改善患者的症状和迹象,这可能与PI3K / AKT途径表达的调节相关,所以调节面包,Cre,Up,Bup和Nag的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号